6 Amendments of Johannes BLOKLAND related to 2006/0136(COD)
Amendment 228 #
Article 4 – paragraph 1 – subparagraph 2
The assessment of the active substance shall first establish whether the approval criteria set out in points 3.6.2 to 3.6.4 and 3.7 of Annex II are satisfied. If these criteria are satisfied the assessment shall continue to establish whether the other approval criteria set out in points 2 and 3 of Annex II are satisfied, including points 3.6.5 and 3.8.2 once specific scientific criteria have been adopted for these annex points in accordance with Article 78(2).
Amendment 238 #
Article 4 – paragraph 7 – subparagraph 1
7. By way of derogation from paragraph 1, where on the basis of documented evidence an active substance is necessary to control a serious danger to plant health, including the development of resistance, which cannot be contained by other availablppropriate means, such active substance may be approved for a time limited period not exceeding five years even if it does not satisfy the criteria set out in points 3.6.3, 3.6.4, 3.6.5 or 3.8.2 of Annex II, provided that the use of the active substance is subject to risk mitigation measures to ensure that exposure of humans and the environment is minimised. For such substances maximum residue levels shall be set in accordance with Regulation (EC) No 396/2005.
Amendment 259 #
Article 30 – paragraph 2
2. In such cases the Member State may start its evaluation regarding a provisional authorisation as soon as there is evidence that the deadlines for the substance authorisation will not be met and shall immediately inform the other Member States and the Commission of its assessment of the dossier and of the terms of the authorisation, giving at least the information provided for in Article 57 (1).
Amendment 260 #
Article 30 – paragraph 2 a (new)
2a. If no decision concerning the active substance has been made before the provisional period of authorisation for the plant protection product has expired, the Member State may extend this authorisation upon application up to the date when a decision is made on the authorisation of the active substance.
Amendment 271 #
Article 40 – paragraph 2 – subparagraph 2
Amendment 315 #
Annex II - point 3.6.5. a (new)
3.6.5a. An active substance shall only be approved if, on the basis of the assessment or other available data and information including a review of the scientific literature, it is not considered to cause a significant risk (affecting 1 in a million citizens) of developmental neurotoxic or immunotoxic properties in humans, taking into account exposure during embryonic/foetal life and/or during childhood as well as likely combination effects.